Neuroprotective effect of CPCGI on Alzheimer's disease and its mechanism

XIAOPENG WANG and JING ZHAO

Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China

Received March 10, 2019; Accepted September 19, 2019

DOI: 10.3892/mmr.2019.10835

Abstract. Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder causing progressive memory loss and cognitive impairment. The aberrant accumulation of amyloid-β (Aβ) and neuroinflammation are two major events in AD. Aβ-induced neurotoxicity and oxidative stress are also involved in the pathogenesis of AD. The purpose of the current study was to investigate the effect of compound porcine cerebroside and ganglioside injection (CPCGI) on the progression of AD, and to explore the molecular mechanism. In vivo and in vitro models of AD were established and treated with CPCGI. Aβ40 and Aβ42 protein levels were detected using western blotting. Production of pro-inflammatory factors [tumor necrosis factor (TNF)-α and interleukin (IL)-1β] and oxidative stress markers [malondialdehyde (MDA), superoxide dismutase (SOD)] and reactive oxygen species (ROS) production were determined. Cell viability and apoptosis were detected using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide assay and flow cytometry analysis respectively. Results demonstrated that CPCGI administration reduced Aβ40 and Aβ42 accumulation, and inhibited inflammatory response and oxidative stress in the in vivo rat model of AD, evidenced by decreased Aβ40 and Aβ42 protein expression, reduced levels of TNF-α and IL-1β, reduced MDA content, enhanced SOD activity, and reduced ROS level. It was found that CPCGI enhanced cell viability and reduced cell apoptosis of Aβ25-35 induced PC12 cells. In addition, the mitogen-activated protein kinase/NF-κB pathway was involved in the protective effect of CPCGI on AD. Taken together, the data demonstrated that CPCGI exerted a protective effect on AD by reducing Aβ accumulation, inhibiting inflammatory response and oxidative stress. In addition to preventing neuronal apoptosis.

Introduction

Few subjects in biomedicine have attracted the interest of the scientific and lay communities alike as has Alzheimer's disease. With the sharp rise in life expectancy during the 20th century, more and more old people from ~49 to >76 years suffer from neurodegenerative disorders in the United States (1-3). Among them, AD appears as the most common form of mental failure in old age (4). The main symptoms of AD are progressive memory disorder, cognitive dysfunction, personality change and language disorder, which seriously affect social, professional and life functions (5). Amyloid β (Aβ) initiates inflammatory reaction in the early stage of disease (6-8). This pathological change can promote the increase of Aβ production and abnormal accumulation, and form cascade amplification effect, resulting in the decrease of neurons and abnormality and causing AD. In addition, Aβ induced neurotoxicity and oxidative stress also participate in the pathogenesis of AD (9). Therefore, the pathogenesis of AD must be understood as soon as possible and corresponding measures taken to prevent and treat it.

Compound porcine cerebroside and ganglioside injection (CPCGI) is a compound preparation, which is used to treat brain dysfunction clinically. It is estimated that each ml of CPCGI contains 0.24 mg monosialotetrahexosyl ganglioside (GM-1), 3.2 mg of polypeptides and 0.125 mg of hypoxanthine (10,11). Hypoxanthine is an important substance in human life, which can improve the metabolism of substance and energy, accelerate the repair of damaged tissue, and restore normal physiological function of anoxic tissue (12). Hypoxanthine, small polypeptide, and amino acid coordination can promote the metabolism of the body. CPCGI has been widely used in China. In clinical studies, CPCGI can significantly shorten the time of fracture healing and promote the curative effect of fracture healing (13). In addition, CPCGI has a significant effect in treating hypoxic ischemic encephalopathy, where it helps to improve the recovery of consciousness and muscle strength, and there is no obvious adverse reaction during the treatment (11,14). A previous study demonstrated that CPCGI could also activate mitochondrial autophagy to improve cerebral ischemia reperfusion injury (10). A clinical study demonstrated that CPCGI can promote the metabolism of brain tissue, participate in the growth, differentiation and regeneration of neurons in brain tissue, and improve the function of cerebral blood circulation and brain metabolism (15).

Correspondence to: Dr Xiaopeng Wang, Department of Neurology, The Second Hospital of Hebei Medical University, 215 Hepingxi Road, Shijiazhuang, Hebei 050000, P.R. China E-mail: wangxp190310@163.com

Key words: Alzheimer's disease, compound porcine cerebroside and ganglioside injection, Alzheimer's disease rat model, Alzheimer's disease PC12 cell model

MOLECULAR MEDICINE REPORTS
However, the effect of CPCGI on AD has not been studied so far. Therefore, the present study investigated the effect of CPCGI on the progress of AD in vivo and in vitro and explored its molecular mechanism.

Materials and methods

Establishment of AD rat model. A total of 40 Wistar rats were selected (age, 10-11 weeks; weight, 240-260 g) from the laboratory animal room of Liaoning University of Traditional Chinese Medicine. The rats fed and drank freely at room temperature (20-22˚C) with 40-50% humidity, and were maintained under a 12-h light/dark cycle. The present study was performed according to the principles and procedures of the National Institutes of Health’s Guide for the Care and Use of Laboratory Animals (16). This study was approved by the Animal Care and Use Committee of the Second Hospital of Hebei Medical University. The rat model of AD was established using Aβ1-42 (Sigma-Aldrich; Merck KGaA) as in previous studies (17-19). The Wistar male rats were randomly divided into 4 groups with 10 rats in each group: Sham, model, model + vehicle (saline) and model + CPCGI (1 ml/kg/d). Rats in the sham group were treated with saline by a gradual intracerebroventricular (icv) injection (1 µl/min) into the lateral ventricle. Rats in the model group were treated with Aβ1-42 (400 pmol/3 µl/rat) by gradual intracerebroventricular (icv) injection (1 µl/min) into the lateral ventricle (17). The AD model rats received CPCGI treatment (1 ml/kg/d; intraperitoneal injection) for 15 consecutive days starting 1 h after AD induction. Rats in the model + vehicle group received an equal amount of saline. At the end of the experiment, the rats were anaesthetized with pentobarbital (40 mg/kg, intraperitoneal injection) before being sacrificed through cervical dislocation (rats without a heartbeat that were not breathing were confirmed as dead). Subsequently, the hippocampal tissues of rats from the different groups were collected. No rats died during the experiment. Tests were performed according to the principles and procedures of the National Institutes of Health’s Guide for the Care and Use of Laboratory Animals. All experiments were carried out according to the principles and procedures of the National Institutes of Health’s Guide for the Care and Use of Laboratory Animals.

Sucrose preference test. On day 12 after CPCGI treatment, to assess anhedonic behavior of rats, the sucrose preference test was performed as in a previous study (17). Briefly, rats were acclimatized to the two-bottle choice paradigm (two identical bottles were placed on the cages) for three days. In order to avoid withdrawal symptoms in rats, each rat was given two bottles, one containing a 2% sucrose solution and the other containing tap water. The two bottles were changed every 12 h to avoid a ‘side’ bias. The amount of the sucrose solution or tap water consumed was detected by weighing the bottles immediately before and after the test. The sucrose preference ratio was calculated as following: Sucrose preference value (%) = sucrose intake (g) x100%/[sucrose intake (g) + water intake (g)].

Tail suspension test. Following the final CPCGI treatment, the tail suspension test was performed as previously described (17). In brief, every rat was individually suspended by the tail using a clamp, 3-4 cm from the end, in a gray wooden enclosure (60x30x20 cm). A square platform was placed under the rat’s forepaws and lightly touching them to avoid hemodynamic stress and limb pain. The immobility time was recorded (in seconds) during the 5-min test period.

PC12 AD cell model establishment and treatment. Rat adrenal pheochromocytoma (PC12) cells were purchased from American Type Culture Collection (ATCC, cat. no. CRL-1721). CPCGI was obtained from Jilin Bunchang Pharmaceutical Co., Ltd. DMEM high-sugar medium, horse serum, and fetal bovine serum were purchased from Gibco (Thermo Fisher Scientific, Inc.). PC12 cells were cultured in DMEM containing 10% fetal bovine serum and 5% horse serum, and cultured at 37˚C with 95% humidity and 5% CO2 (20). PC12 cells were divided into control, model, model + vehicle (PBS) and model + CPCGI. In the model + vehicle and model + CPCGI groups, PC12 cells were pre-treated with PBS and CPCGI separately for 1 h before stimulation with 50 µM Aβ25-35 (Sigma-Aldrich; Merck KGaA) for 24 h. PC12 cells in the model group were stimulated with 50 µM Aβ25-35 for 24 h (21). Cells in the control group were not subjected to any treatment. Subsequently, PC12 cells in each group were subjected to the following experiments.

Reverse transcription-quantitative (RT-q) PCR. Total RNA from tissues (100 mg) was collected by using TRIzol® reagent (Thermo Fisher Scientific, Inc.) and reverse transcribed into cDNA using PrimeScript RT Reagent Kit (Takara Bio, Inc.) according to the manufacturer’s protocols. The temperature protocol for the reverse transcription reaction was 25˚C for 5 min, 42˚C for 60 min and 80˚C for 2 min. qPCR was performed to analyze gene expression using the cDNA the SYBR RT-PCR kit (Takara Bio, Inc.) according to the manufacturer’s protocols. The thermocycling conditions were as follows: 95˚C for 5 min, followed by 38 cycles of denaturation at 95˚C for 15 sec and annealing/elongation at 60˚C for 30 sec. Primer sequences were: GAPDH, forward 5'-CTTGTGTATCGTGGAAAGACTC-3'; reverse 5'-GTAGAGGCAGGATGATTCTT-3'; Aβ42, forward 5'-ATGGCCAGCAGGAACTCT-3'; reverse 5'-GGCAATCACCGCCGCAC-3'; GAPDH was used as the internal control, and the gene expression was quantified by the 2^(-ΔΔCt) method (22).

Western blot analysis. Protein expression was detected using western blotting. Radioimmunoprecipitation assay buffer (Auragene Bioscience) was used to extract the proteins from hippocampus or PC12 cells. A bicinchoninic acid protein quantitative kit (Thermo Fisher Scientific, Inc.) was used to detect protein concentrations in line with the manufacturer's instructions. 10% SDS-PAGE gel electrophoresis was used to isolate proteins (30 µg/lane), and then the proteins were transferred onto PVDF membranes (EMD Millipore). 5% skimmed milk was used to block the membrane at room temperature for 1 h, and then the membranes were incubated with primary antibodies: β-Amyloid (for Aβ42 and Aβ40 detection; cat no. 8243; 1:1,000; Cell Signaling Technology, Inc.), Bcl-2 (cat no. ab196495; 1:1,000; Abcam), Bax (cat no. ab32503; 1:1,000; Abcam), cleaved caspase3 (cat no. ab49822; 1:1,000; Abcam), pro-caspase3 (cat no. ab183179; 1:1,000; Abcam), phospho- activated (p)-p38 (cat no. ab4922; 1:1,000; Abcam), p38 (cat no. ab170099; 1:1,000; Abcam), p65 (cat no. ab16502; 1:1,000; Abcam), p-p65 (cat no. ab86299; 1:1,000; Abcam), and β-actin.
(cat no. ab179467; 1:1,000; Abcam) at room temperature for 3 h. Subsequently, the PVDF membranes were hybridized with horseradish peroxidase-conjugated anti-rabbit IgG secondary antibody (cat. no. 7074; 1:2,000; Cell Signaling Technology, Inc.) for 1 h. Finally, ECL reagent (Applygen Technologies, Inc.) was used to visualize protein bands. The band density was semi-quantified with Gel-Pro Analyzer densitometry software (version 6.3, Media Cybernetics, Inc.).

Enzyme linked immunosorbent assay (ELISA). The expression of TNF-α (cat. no. PTS16) and IL-1β (cat. no. P303) in the hippocampus of rats from different groups were detected using ELISA kits (Beyotime Institute of Biotechnology) according to the manufacturer's instructions.

SOD activity and MDA content measurement. To determine SOD activity (cat. no. S0101) and MDA content (cat. no. S0131) in the hippocampus of rats, commercial colorimetric detection kits (Beyotime Institute of Biotechnology) were performed following the manufacturer's instructions.

Reactive oxygen species (ROS) production detection. A Reactive Oxygen Species Assay kit (cat. no. S0033, Beyotime Institute of Biotechnology) was used to determine the production of ROS in the hippocampus of rats according to the manufacturer's instructions. The ROS level was expressed as the percentage of the dichlorofluorescein (DCF) fluorescence level in control group whose DCF level was set to 100%.

Cell viability analysis. Cell viability was determined by the conventional MTT assay. Following treatment, PC12 cells were seeded in 96-well plates (10^3 cells/well) and incubated at 37°C for 24 h. Then MTT solution (10 µl) was added to each well and the cells were incubated for further 4 h at 37°C. Subsequently, 100 µl DMSO (Nanjing KeyGen Biotech Co., Ltd.) was used to dissolve the formazan crystals. Finally, the absorbance was measured at the wavelength of 490 nm by using a micro-plate reader (Synergy2, BioTek Instruments, Inc.).

Apoptosis assay. Flow cytometry (BD Accuri Flow Cytometer, BD Biosciences) was performed to analyze cell apoptosis. PC12 cells were treated with or without CPCGI for 48 h. Then, the cell apoptosis was determined by using the Annexin V-fluorescein isothiocyanate/propidium iodide apoptosis detection kit [cat. no. 70-AP101-100; Multisciences (Lianke) Biotech Co., Ltd.] in accordance with the manufacturer's protocols. FlowJo 7.6 software (FlowJo LLC) was used to analyze the cell apoptosis rate.

Statistical analysis. Statistical analysis was performed using SPSS 18.0 (SPSS, Inc.). All experiments were performed three times. Data are presented as mean ± standard deviation. The differences between groups were analyzed by one-way analysis of variance with Tukey's post hoc test. P<0.05 was considered to indicate a statistically significant difference.

Results

CPCGI ameliorates AD-associated symptoms of rats induced by Aβ1-42. To study the therapeutic effect of CPCGI on AD, the rat model of AD was constructed and then treated with CPCGI. It was found that the reduced percentage of sucrose preference of rats induced by Aβ1-42 was significantly increased by CPCGI treatment (Fig. 1A). The enhanced immobility time of rats caused by Aβ1-42 administration was significantly reduced by CPCGI treatment (Fig. 1B).

CPCGI treatment inhibited inflammatory response and oxidative stress in AD model rats induced by Aβ1-42. Results suggested that compared with sham group, the protein expression of Aβ40 and Aβ42 in the hippocampus of AD model rats was markedly increased, while CPCGI significantly decreased the expression of Aβ40 and Aβ42 (Fig. 2A). Compared with the sham group, the mRNA expression of Aβ40 and Aβ42 in the hippocampus of AD model rats was significantly increased, while CPCGI significantly decreased the mRNA expression of Aβ40 and Aβ42 (Fig. 2B and C). Compared with the rats from the sham group, the production of TNF-α and IL-1β in the hippocampus of AD model rats was significantly increased, and these increases were inhibited by CPCGI treatment (Fig. 2D and E). In addition, the content of MDA in the hippocampus of Aβ1-42 induced rats was significantly increased (Fig. 2F), the activity of SOD was significantly decreased (Fig. 2G), and the ROS level significantly enhanced (Fig. 2H). CPCGI treatment significantly reduced the content of MDA, increased the activity of SOD, and decreased ROS level in the hippocampus of AD model rats (Fig. 2F-H).
CPCGI reduced the protein expression of Aβ40 and Aβ42 in Aβ25-35 induced PC12 cells. In order to detect the protein expression of Aβ40 and Aβ42, western blot analysis was used. The results demonstrated that the protein expression of Aβ40 and Aβ42 in Aβ25-35 induced PC12 cells increased significantly compared with the control group, and that CPCGI could decrease the protein expression of Aβ40 and Aβ42 in Aβ25-35 induced PC12 cells (Fig. 3A-C).

CPCGI enhanced the viability of Aβ25-35 induced PC12 cells. MTT assay was used to investigate the effect of CPCGI on the viability of PC12 cells. The results demonstrated that compared with the control group, the viability of PC12 cells was significantly enhanced by CPCGI.
decreased in Aβ25-35 treated PC12 cells. CPCGI treatment could significantly increase the viability of Aβ25-35 induced PC12 cells (Fig. 4A).

CPCGI reduced apoptosis of Aβ25-35 induced PC12 cells. Flow cytometry was used to analyze the effect of CPCGI on apoptosis in PC12 cells. Compared with the control
group, the apoptosis of PC12 cells in AD cell model group increased significantly. The apoptosis of Aβ25-35 induced PC12 cells (Fig. 4B and C) was significantly reduced by CPCGI treatment. In addition, the protein expression of p38, p-p38, p-p65 and β-actin in PC12 cells was detected using western blot analysis. The results demonstrated that the protein expression of p38 and p-p38 in the control group were significantly higher than that in the control group. CPCGI treatment significantly reduced the protein expression of p-p38 and p-p65 and the ratio of p-p38/p38 and p-p65/p65 in Aβ25-35 induced PC12 cells, and these changes were inhibited by CPCGI treatment (Fig. 4D-H).

**CPCGI reduced p-p38 and p-p65 expression in Aβ25-35 induced PC12 cells.** To explore the mechanism by which CPCGI affected AD, the p38 mitogen-activated protein kinase (MAPK)/NF-κB pathway was analyzed. In addition, the protein expression of p38, p65, p-p38 and p-p65 in PC12 cells was detected using western blot analysis. The results demonstrated that the protein expression of p-p38 and p-p65 in Aβ25-35 induced PC12 cells were significantly higher than that in the control group. CPCGI treatment significantly reduced the protein expression of p-p38 and p-p65 and the ratio of p-p38/p38 and p-p65/p65 in Aβ25-35 induced PC12 cells (Fig. 5A-C), indicating the inhibitory effect of CPCGI on p38MAPK/NF-κB pathway in Aβ25-35 induced PC12 cells.

**Discussion**

Alzheimer’s disease is a degenerative disease of the central nervous system characterized by progressive memory impairment and mental retardation (1,5). With the aging of the world population, the incidence of Alzheimer’s disease is increasing, therefore, it is urgent to find new and effective methods for treating AD. In recent years, a great deal of research has been performed on the etiology and pathogenesis of Alzheimer’s disease (23,24). Aβ (6-8), inflammatory factors (25) and oxidative stress markers MDA and SOD (26,27) have been found to serve a leading role in the occurrence and development of AD. Previous studies have found that folic acid could improve learning and memory in rats with AD by directly or indirectly inhibiting or clearing the deposition of Aβ in the hippocampus and olfactory region (28-30). In addition, zuo-gui pills, a classic TCM formulation (31,32), can effectively increase the activity of SOD and decrease the content of MDA in brain tissue of AD model rats (33). In the study of CPCGI, a previous study found that CPCGI has a neuroprotective effect on middle cerebral artery occlusion injured rats by inhibiting apoptosis and improving synaptic and mitochondrial function (10). In a study of the protective effect of CPCGI on cerebral ischemia-reperfusion injury in rats, the results suggested that one of the neuroprotective mechanisms of CPCGI may be related to activation of mitochondrial autophagy and improvement of mitochondrial function (15).

Previous studies have demonstrated that CPCGI has neuroprotective effect (10,11,15), but its neuroprotective mechanism for AD is still unclear, therefore, the present study investigated the effect of CPCGI on AD. In the present study, the rat model of AD was established using Aβ1-42 and then treated with CPCGI. Depression is prevalent in patients with AD (34,35). Previous studies have revealed that intracerebroventricular or hippocampal injection of Aβ1-42 results in depressive-like symptoms in rats (36-39). Therefore, the present study determined the effect of CPCGI on the percentage of sucrose preference and the immobility time of rats with AD, and found that CPCGI significantly enhanced the percentage of sucrose preference of AD rats and reduced the immobility time of rats treated with Aβ1-42. Each ml of CPCGI contains 0.24 mg Monosialotetrahexosyl ganglioside (GM-1), 3.2 mg of polypeptides, and 0.125 mg of hypoxanthine (10,11). As GM-1 (40,41) and polypeptides (42) all have been reported to have neuroprotective effects, it was hypothesized that CPCGI may serve a protective role in AD mainly through GM-1 and polypeptides, however, this need further research.

The protein expression of Aβ40 and Aβ42, inflammatory factors TNF-α and IL-1β, the MDA secretion and SOD activity associated with oxidative stress markers, and ROS production, which are involved in the occurrence and development of AD, were identified in the hippocampus of AD model rats. The findings indicated that CPCGI administration significantly decreased the protein expression of Aβ40 and Aβ42, and that the production of TNF-α and IL-1β in the hippocampus of AD model rats was also reduced by CPCGI treatment. CPCGI treatment significantly reduced the MDA content, increased SOD activity and reduced ROS level in the hippocampus of AD model rats. However, as the detection of injected Aβ may be controversial because of the detected expression could be due to the injected Aβ, the expression of injected Aβ in rats or PC12 cells were not measured in the present study.

An in vitro model of AD was established by subjecting PC12 cells to Aβ25-35, and it was found that the viability of AD model cells significantly decreased and the apoptosis of cells increased. The results of the current study were consistent...
with previous studies (43,44): CPCGI treatment significantly enhanced the viability of PC12 cells induced by Aβ25-35 and reduced cell apoptosis.

The MAPK/NF-κB pathway, serves important roles in the regulation of cell growth and inflammatory response, and has been revealed to be activated during the development of AD (45,46). Thus, to explore the mechanism by which CPCGI affected AD, the p38MAPK/NF-κB pathway was analyzed. As expected, it was observed that the activated p38MAPK/NF-κB pathway caused by Aβ25-35 induction was inhibited by CPCGI treatment.

In conclusion, the results of the present study suggested that CPCGI served a protective role in AD development by reducing Aβ accumulation, inhibiting inflammatory response and oxidative stress, and preventing neuronal apoptosis by inhibiting MAPK/NF-κB signaling pathway activation. However, the present study is a preliminary study of the role of CPCGI in AD, and has some limitations. For example, the pathological changes of AD rats were not analyzed using microscopy. The p38MAPK/NF-κB pathway was not analyzed in vivo. A group of p38 specific inhibitor or NF-κB specific inhibitor combination therapies was not conducted in the present study nor did it investigate the effect of CPCGI on normal rats and PC12 cells. In order to make the role of CPCGI in AD more convincing, more research is needed. For instance, whether CPCGI serves a role in AD by directly affecting p38MAPK and NF-κB signaling in vivo and in vitro should be investigated. In addition, the effect of CPCGI on normal rats and normal PC12 cells should be studied.

Acknowledgements
Not applicable.

Funding
No funding was received.

Availability of data and materials
All datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions
XW performed study design, data collection, statistical analysis, data interpretation and manuscript preparation. JZ performed data collection and statistical analysis.

Ethics approval and consent to participate
The present study was performed according to the principles and procedures of the National Institutes of Health’s Guide for the Care and Use of Laboratory Animals. This study was approved by the Animal Care and Use Committee of the Second Hospital of Hebei Medical University.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References


